<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5006528 - Treating schizophrenia - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Treating schizophrenia"><meta name="DC.contributor" content="Yasuo Oshiro" scheme="inventor"><meta name="DC.contributor" content="Seiji Sato" scheme="inventor"><meta name="DC.contributor" content="Nobuyuki Kurahashi" scheme="inventor"><meta name="DC.contributor" content="Otsuka Pharmaceutical Co., Ltd." scheme="assignee"><meta name="DC.date" content="1989-10-20" scheme="dateSubmitted"><meta name="DC.description" content="A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R1 is a C1- C3 alkoxy group)), a group of the formula ##STR3## ((wherein R2 and R 3 are each, at the same time, a chlorine atom, a bromine atom; and R4 is a hydrogen atom or a chlorine atom)), 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR4## ((wherein R5 is a chlorine atom or a bromine atom; and R6 is a methyl group)); the carbon-carbon bond between 3- and 4-position in the carbostyril skeleton is a single or double bond)."><meta name="DC.date" content="1991-4-9" scheme="issued"><meta name="DC.relation" content="JP:S58203968" scheme="references"><meta name="DC.relation" content="US:4824840" scheme="references"><meta name="citation_patent_number" content="US:5006528"><meta name="citation_patent_application_number" content="US:07/424,719"><link rel="canonical" href="http://www.google.com/patents/US5006528"/><meta property="og:url" content="http://www.google.com/patents/US5006528"/><meta name="title" content="Patent US5006528 - Treating schizophrenia"/><meta name="description" content="A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R1 is a C1- C3 alkoxy group)), a group of the formula ##STR3## ((wherein R2 and R 3 are each, at the same time, a chlorine atom, a bromine atom; and R4 is a hydrogen atom or a chlorine atom)), 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR4## ((wherein R5 is a chlorine atom or a bromine atom; and R6 is a methyl group)); the carbon-carbon bond between 3- and 4-position in the carbostyril skeleton is a single or double bond)."/><meta property="og:title" content="Patent US5006528 - Treating schizophrenia"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("eC_uU-zzN4fesAT3s4CoCg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("DEU"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("eC_uU-zzN4fesAT3s4CoCg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("DEU"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5006528?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5006528"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=-rgvBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5006528&amp;usg=AFQjCNHWRMvpS-ZXbhR2WQa7JjSiW-DMSg" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5006528.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5006528.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5006528" style="display:none"><span itemprop="description">A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R1 is a C1- C3 alkoxy group)), a group of the formula ##STR3## ((wherein R2 and R 3 are each, at the same time, a chlorine atom, a bromine atom; and R4 is a...</span><span itemprop="url">http://www.google.com/patents/US5006528?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5006528 - Treating schizophrenia</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5006528 - Treating schizophrenia" title="Patent US5006528 - Treating schizophrenia"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5006528 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 07/424,719</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Apr 9, 1991</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Oct 20, 1989</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Oct 31, 1988</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CN1028104C">CN1028104C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1042537A">CN1042537A</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE68925405D1">DE68925405D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE68925405T2">DE68925405T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE122004000043I1">DE122004000043I1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE122004000043I2">DE122004000043I2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0367141A2">EP0367141A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0367141A3">EP0367141A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0367141B1">EP0367141B1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">07424719, </span><span class="patent-bibdata-value">424719, </span><span class="patent-bibdata-value">US 5006528 A, </span><span class="patent-bibdata-value">US 5006528A, </span><span class="patent-bibdata-value">US-A-5006528, </span><span class="patent-bibdata-value">US5006528 A, </span><span class="patent-bibdata-value">US5006528A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Yasuo+Oshiro%22">Yasuo Oshiro</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Seiji+Sato%22">Seiji Sato</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Nobuyuki+Kurahashi%22">Nobuyuki Kurahashi</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Otsuka+Pharmaceutical+Co.,+Ltd.%22">Otsuka Pharmaceutical Co., Ltd.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5006528.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5006528.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5006528.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (2),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (116),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (6),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (12)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5006528&usg=AFQjCNFeLnYoF9IdvtZc8TH_rC3v5Rk_mQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5006528&usg=AFQjCNF2BXthReWG9KSgD3K9docuiBiGuQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5006528A%26KC%3DA%26FT%3DD&usg=AFQjCNGhW0GWTBQgfRL7S43j5GmTNbA7lA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129403345" lang="EN" load-source="ifi">Treating schizophrenia</invention-title></span><br><span class="patent-number">US 5006528 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA131119062" lang="EN" load-source="patent-office"> <div class="abstract">A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R<sup>1</sup> is a C<sub>1-</sub> C<sub>3</sub> alkoxy group)), a group of the formula ##STR3## ((wherein R<sup>2</sup> and R <sup>3</sup> are each, at the same time, a chlorine atom, a bromine atom; and R<sup>4</sup> is a hydrogen atom or a chlorine atom)), 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR4## ((wherein R<sup>5</sup> is a chlorine atom or a bromine atom; and R<sup>6</sup> is a methyl group)); the carbon-carbon bond between 3- and 4-position in the carbostyril skeleton is a single or double bond).</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(19)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5006528-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5006528-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(21)</span></span></div><div class="patent-text"><div mxw-id="PCLM59049192" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A carboxtyril compound or salt thereof of the formula, ##STR34## wherein R is a group of the formula ##STR35## wherein R<sup>1</sup> is a C<sub>1</sub> -C<sub>3</sub> alkoxy group; a group of the formula ##STR36## wherein R<sup>2</sup> and R<sup>3</sup> are at the same time, both chlorine atoms, or both bromine atoms and R<sup>4</sup> is a hydrogen atom or a chlorine atom; a 2-methyl-3-nitrophenyl group; a 3,5-dichlorophenyl group; or a group of the formula ##STR37## wherein R<sup>5</sup> is a chlorine atom or a bromine atom and R<sup>6</sup> is a methyl group; the carbon-carbon bond between the 3- and 4-positions in the carboxtyril skeleton being a single or a double bond.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The carboxtyril compound or salt thereof of claim 1, wherein R is a group of the formula ##STR38##</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The carboxtyril compound or salt thereof of claim 2, wherein R<sup>1</sup> is a methoxy group or an ethoxy group.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The carboxtyril compound or salt thereof of claim 1, wherein R is a group of the formula ##STR39##</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The carbostyril compound or salt thereof of claim 4, wherein R<sup>2</sup> and R<sup>3</sup> are chlorine atoms and R<sup>4</sup> is a hydrogen atom.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The carbostyril compound or salt thereof of claim 4, wherein R<sup>2</sup> and R<sup>3</sup> are bromine atoms and R<sup>4</sup> is a hydrogen atom.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The carbostyril compound or salt thereof of claim 4, wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are chlorine atoms.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The carbostyril compound or salt thereof of claim 1, wherein R is a 2-methyl-3-nitrophenyl group or a 3,5-dichlorophenyl group.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. The carbostyril compound or salt thereof of claim 1, wherein R is a group of the formula ##STR40##</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The carbostyril compound or salt thereof of claim 9, wherein R<sup>5</sup> is a chlorine atom.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The carbostyril compound or salt thereof of claim 9, wherein R<sup>5</sup> is a bromine atom.</div>
    </div>
    </div> <div class="claim"> <div num="12" class="claim">
      <div class="claim-text">12. 7-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.</div>
    </div>
    </div> <div class="claim"> <div num="13" class="claim">
      <div class="claim-text">13. 7-{4-[4-(b 2,3-Dichlorophenyl)-1-piperazinyl]-butoxy}carbostyril.</div>
    </div>
    </div> <div class="claim"> <div num="14" class="claim">
      <div class="claim-text">14. 7-{4-[4-(2-Ethoxyphenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.</div>
    </div>
    </div> <div class="claim"> <div num="15" class="claim">
      <div class="claim-text">15. 7-{4-[4-]2-Ethoxyphenyl)-1-piperazinyl]butoxy}-carbostyril.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" class="claim">
      <div class="claim-text">16. A pharmaceutical composition for treating schizophrenia containing, as the active ingredient, a carbostyril compound or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" class="claim">
      <div class="claim-text">17. The pharmaceutical composition of claim 16, wherein the carbostyril compound or salt thereof is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" class="claim">
      <div class="claim-text">18. The pharmaceutical composition of claim 16, wherein the carbostyril compound or salt thereof is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}carbostyril.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" class="claim">
      <div class="claim-text">19. The pharmaceutical composition of claim 16, wherein the carbostyril compound or salt thereof is 7-{4-[4-(2-ethoxyphenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" class="claim">
      <div class="claim-text">20. The pharmaceutical composition of claim 16, wherein the carbostyril compound or salt thereof is 7-{4-[4-(2-ethoxyphenyl)-1-piperazinyl]butoxy}carbostyril.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" class="claim">
      <div class="claim-text">21. The pharmaceutical composition for treating schizophrenia containing, as the active ingredient, a carbostyril compound or pharmaceutically acceptable salt thereof of claim 3 and a pharmaceutically acceptable carrier.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66068526" lang="EN" load-source="patent-office" class="description">
    <heading>FIELD OF THE INVENTION</heading> <p>The present invention relates to novel carbostyril derivatives. More particularly, the invention relates to novel carbostyril derivatives and salts thereof, processes for preparing said carbostyril derivatives and salts thereof, as well as pharmaceutical compositions for treating schizophrenia containing, as the active ingredient, said carbostyril derivative or salt thereof.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>Schizophrenia is the most common type of psychosis caused by an excessive neurotransmission activity of the dopaminergic nervous system in the central nervous system. [Cf. "Hypothesis of Excessive Dopamine" by Michio Tohru: TAISHA (Metabol:sm), Vol. 22, pp. 49, (1985); and Pharmacia Review, No. 10, "KOKORO-TO-KUSURI (Mind and Drugs)" edited by Pharmaceutical Society of Japan.]</p>
    <p>Heretofore, a number of drugs, having the activity for blocking the neurotransmission of dopaminergic receptor in the central nervous system, have been developed, the example for said drugs are phenothiazine-type compounds such as Chlorpromazine; butyrophenone-type compounds such as Haloperidol; and benzamide-type compounds such as Sulpiride. These known drugs are now used widely for the purpose of improving so-called positive symptoms in the acute period of schizophrenia such as hallucinations, delusions and excitations and the like.</p>
    <p>However, many of these drugs are considered as not effective for improving so-called the negative symptoms which are observed in the chronic period of schizophrenia such as apathy, emotional depression, hypopsychosis and the like. In addition to the above, these drugs give important side-effects such as akathisia, dystonia, Parkinsonism dyskinesia and late dyskinesia and the like, which are caused by blocking the neurotransmission of dopaminergic receptor in the striate body. Furthermore, other side-effects such as hyperprolactinemia and the like given by these drugs are become other problems. [Cf. G. M. Simpson, E. H. Pi, and J. J. Sramek, Jr.: Drugs, Vol. 21, pp. 138 (1981).]</p>
    <p>Under these circumstances, development of drugs for treating schizophrenia having safety and clinically effectiveness have been eagerly expected.</p>
    <p>The present inventors have made an extensive study for the purpose of developing drugs for treating schizophrenia, which would be not only effective for improving the negative symptoms, but also effective for improving the positive symptoms of schizophrenia, furthermore such drugs would have less side-effects as compared with those shown by drugs known in prior art. As the result, the present inventors have successfully found carbostyril derivatives having strong activity for blocking neurotransmission of dopaminergic receptor. As to the side-effects given by known drugs for treating schizophrenia are for example, in the case of phenothiazine-type drugs, the orthostatic hypotension and hypersedation on the basis of strong α-blocking activity; and in the case of drugs having strong activity for blocking neurotransmission of dopaminergic receptor, the side-effects are so-called extrapyramidal tract syndromes such as catalepsy, akathisia, dystonia and the like caused by the blocking neurotransmission of dopaminergic receptor in the atriate body.</p>
    <p>Among carbostyril derivatives known in prior art, those disclosed in U.S. Pat. No. 4,734,416; Canadian Patent No. 1,117,110; British Patent No. 2,017,701; German Patent Nos. 2,911,108, 1,912,105 and 2,953,723; Japanese Patent Kokai (Laid-open) Nos. 54-130,587 (1979), 55-127,371, (1980) and 62-149,664 (1987) are having chemical structural formulas of upper conception of carbostyril derivatives of the present invention.</p>
    <p>Furthermore, carbostyril derivatives disclosed in U.S. Pat. No. 4,234,585 and European Patent No. 226,441 have chemical structural formula similar to that of carbostyril derivatives of the present invention, but the pharmacological activities thereof are different from those of possessed by the carbostyril derivatives of the present invention.</p>
    <p>In addition to the above, the carbostyril derivatives disclosed in U.S. Pat. No. 4,234,584 have chemical structural formula similar to that of carbostyril derivatives of the present invention and also have pharmacological activities similar to those of shown by carbostyril derivatives of the present invention.</p>
    <p>Carbostyril derivatives disclosed in Australian Patent No. 50252/85, Japanese Patent Kokai (Laid-open) Nos. 58-43952 (1983), 56-49359 (1981), 56-49360 (1981) and 56-49361 (1981) have substituents different from those of the carbostyril derivatives of the present invention.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>It is an object of the present invention to provide novel carbostyril derivatives and salts thereof.</p>
    <p>A further object of the present invention is to provide processes for preparing said carbostyril derivatives and salts thereof.</p>
    <p>A still further object of the present invention is to provide a pharmaceutical composition for treating schizophrenia.</p>
    <heading>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS</heading> <p>Carbostyril derivatives of the present invention and salts thereof are represented by the general formula (1) as follows: ##STR5## (wherein R is a group of the formula ##STR6## (wherein R<sup>1</sup> is a C<sub>1</sub> -C<sub>3</sub> alkoxy group)), a group of the formula ##STR7## wherein R<sup>2</sup> and R<sup>3</sup> are each, at the same time, a chlorine atom, a bromine atom; and R<sup>4</sup> is a hydrogen atom or a chlorine atom, 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR8## wherein R<sup>5</sup> is a chlorine atom or a bromine atom; and R<sup>6</sup> is a methyl group ; the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or double bond), and salts thereof.</p>
    <p>Carbostyril derivatives and salts thereof represented by the general formula (1) possess strong activity for blocking the neurotransmission effect of dopaminergic receptor, with a weak α-blocking activity which have been found during the step of research and development of a number of carbostyril derivatives, thus when the strength of α-blocking activity of a carbostyril derivative is defined as the dose (ED<sub>50</sub>, mg/kg, per os) which is required to inhibits 50% of deth of mice being administered with epinephrine, and also the strength of activity for blocking the neurothransmission effect of dopaminergic receptor which is the main activity of carbostyril derivative, is defined as the dose (ED<sub>50</sub>, mg/kg, per os) which is required to inhibits 50% of stereotypy of mice induced by administration with apomorphine, the agonist of dopamine. The present invention was successfully completed by the above-mentioned findings of said activitied.</p>
    <p>Carbostyril derivatives represented by the general formula (1) can be prepared by various methods, the examples for said methods are as follows:</p>
    <heading>Reaction Formula-1 ##STR9## (wherein R and the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton are the same as defined above; and X<sup>1</sup> is a halogen atom or a group which can carry out a substitution reaction similar to a halogen atom, the examples of such group is a mesityloxy group and tosyloxy group and the like).</heading> <p>The reaction of a compound of the general formula (3) with a compound of the general formula (4) can be carried out in the absence or presence of a common inert solvent, under temperature condition of room temperature to 200° C., preferably at 60° to 120° C., and the reaction is completed in about several hours to 24 hours. As to the inert solvent used in this reaction, any solvents for example, ethers such as dioxane, tetrahydrofuran, ethylene glycol dimethyl ether and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; lower alcohols such as methanol, ethanol, isopropanol and the like; polar solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile and the like can be used. The reaction can be advantageously carried out by using a basic compound as the dehydrohalogenating agent. As to said basic compound, an inorganic basic compound such as calcium carbonate, sodium carbonate, sodium hydroxide, sodium hydrogen carbonate, sodium amide, sodium hydride and the like; and an organic basic compound such as triethylamine, tripropylamine, pyridine, quinoline and the like can be used. Furthermore, the above-mentioned reaction can be carried out, if necessary, by adding an alkali metal iodide such as potassium iodide, sodium iodide or the like as the reaction accelarator. In the above-mentioned reaction, the ratio of used amount of a compound of the general formula (3) to a compound of the general formula (4) may be an equimolar quantity or more, preferably an equimolar quantity to 5 times the molar quantity, more preferably, an equimolar quantity to 1.2 times the molar quantity of the latter to the former.</p>
    <heading>Reaction Formula-2 ##STR10## (wherein R and the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton are the same as defined above; and X<sup>2</sup> is a halogen atom).</heading> <p>In the Reaction Formula-2, the reaction of a compound represented by the general formula (5) with a compound represented by the general formula (6) can be carried out, preferably by using a basic compound as the dehydrohalogenating agent, in a suitable solvent at room temperature to 200° C., preferably at 50° to 150° C. for within several hours to 15 hours. As to the suitable solvent used in the above reaction, lower alcohols such as methanol, ethanol, isopropanol and the like; ketones such as acetone, methyl ethyl ketone and the like; ethers such as dioxane, diethylene glycol dimethyl ether and the like; aromatic hydrocarbons such as toluene, xylene and the like; DMF, DMSO, hexamethylphosphoryl triamide and the like can be exemplified. As to the basic compound to be used as the dehydrohalogenating agent, an inorganic basic substance such as sodium hydorxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydride, metallic potassium, sodium amide and the like; an alkali metal alcoholate such as sodium methoxide, sodium ethoxide, potassium ethoxide and the like; as well as an organic basic compound for example, tertiary amines such as pyridine, quinoline, triethylamine, tripropylamine and the like can be exemplified. Furthermore, the above-mentioned reaction can be carried out by using an alkali metal iodide such as potassium iodide, sodium iodide and the like as the reaction accelerator. The ratio of used amount of a compound of the formula (5) to compound of the formula (6) is not specifically restricted, and an equimolar quantity or more of the latter, generally an equimolar to 5 times the molar quantity, preferably an equimolar to 1.2 times of the molar quantity of the latter may be used to one molar quantity of the former.</p>
    <heading>Reaction Formula-3 ##STR11## (wherein R, X<sup>2</sup> and the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton are the same as defined above).</heading> <p>The reaction of a compound of the general formula (7) with a compound of the general formula (8) is carried out in a suitable solvent, and in the absence or presence of a basic compound. As to the solvent used in this reaction, aromatic hydrocarbons such as benzene, toluene, xylene and the like; lower alcohols such as methanol, ethanol, propanol, butanol and the like; pyridine, acetone, DMF, DMSO, hexamethylphosphoryl triamide and the like can be exemplified. As to the basic compound used in this reaction, inorganic basic compounds such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride and the like; organic basic compounds such as triethylamine and the like can be exemplified. A compound of the general formula (8) may be used at least an equimolar quantity, preferably an equimolar to 3 times the molar quantity thereof to one molar quantity of a compound of the general formula (7). The reaction is carries out, generally at room temperature to 180° C., preferably at 80° to 150° C., and is completed in about 3 to 30 hours.</p>
    <heading>Reaction Formula-4 ##STR12## (wherein R, X<sup>1</sup> and the carbon-carbon bond between 3- and 4- positions in the carbostyril skeleton are the same as defined above).</heading> <p>The reaction of a compound of the formula (9) with a compound of the formula (10) can be carried out in a suitable solvent and in the absence or presence of a basic compound. As to the solvent used in this reaction, water; a lower alcohols such as methanol, ethanol, isopropanol, butanol and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; acetic acid, ethyl acetate, DMF, DMSO, hexamethylphosphoryl triamide and the like can be exemplified. As to the basic compound used in this reaction, an inorganic basic compound such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium hydroxide and the like; an alkali metal alcoholate such as sodium methylate, sodium ethylate and the like; an organic basic compound such as 1,5-diazabicyclo[4.3.0]nonene-5 (DBN), 1,8-diazabicyclo[5.4.0]-undecene-7 (DBU), 1,4-diazabicyclo[2.2.2]octane (DABCO) and the like can be exemplified. A compound of the general formula (10) may be used generally, at least an equimolar quantity, preferably an equimolar to 5 times the molar quantity to one molar quantity of compound of the general formula (9). The reaction is generally carried out at 40° to 120° C., preferably at about 70° to 100° C., and is completed in about 1 to 15 hours.</p>
    <heading>Reaction Formula-5 ##STR13## (wherein R, X<sup>1</sup> and the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton are the same as defined above).</heading> <p>The reaction of a compound of the general formula (11) with a compound of the general formula (12) is carried out under conditions similar to those employed in the reaction of a compound of the general formula (9) with a compound of the general formula (10).</p>
    <p>In the above-mentioned Reaction Formula-1, a compound of the general formula (4) used as one of the starting materials is prepared by a method as shown in Reaction Formula-6 as follows.</p>
    <heading>Reaction Formula-6 ##STR14## (wherein R and X<sup>1</sup> are the same as defined above).</heading> <p>The reaction of a compound of the formula (10) with a compound of the formula (13) is carried out by methods similar to those employed in the reaction of a compound of the formula (9) with a compound of the formula (10).</p>
    <p>Carbostyril derivative represented by the formula (1) of the present invention can easily be converted into its acid-addition salt by reacting it with a pharmaceutically acceptable acid. The examples of such acid includes inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; organic acids such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid and the like. Among carbostyril derivatives represented by the formula (1) of the present invention, those having acidic group can easily be converted into their salts by reacting with basic compounds. The examples of such basic compounds includes sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium hydrogen carbonate and the like. The desired compounds prepared by the procedures in the above-mentioned various reaction formulas can easily be isolated and purified by usual separation means such as solvent extraction, dilution, recrystallization, column chromatography, preparative thin layer chromatography and the like.</p>
    <p>Carbostyril derivatives represented by the general formula (1) can be used in the form of usual pharmaceutical compositions which are prepared by using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, surface active agents, lubricants and the like. As to the pharmaceutical compositions, various types of administration unit forms can be selected depending on the therapeutical purposes, and the examples of pharmaceutical compositions are tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injection preparations (solutions and suspensions) and the like. For the purpose of shaping the pharmaceutical composition in the form of tablets, any excipients which are known and used widely in this field can also be used, for example carriers such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and the like; binders such as water, ethanol, propanol, simple sirup, glucose solutions, starch solutions, gelatin solutions, carboxymethyl cellulose, shelac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone and the like; disintegrating agents such as dried starch, sodium alginate, agar powder, laminalia powder, sodium hydrogen carbonate, calcium carbonate, fatty acid esters of polyoxyethylene sorbitan, sodium laurylsulfate, monoglyceride of stearic acid, starch, lactose and the like; disintegration inhibitors such as white sugar, stearin, coconut butter, hydrogenated oils; absorption accelerators such as quaternary ammonium base, sodium laurylsulfate and the like; wetting agents such as glycerin, starch and the like; adsorbing agents such as starch, lactose, kaolin, bentonite, colloidal silicic acid and the like; and lubricants such as purified talc, stearates, boric acid powder, polyethylene glycol and the like. If tablets are desired, they can be further coated with the usual coating materials to make the tablets as sugar coated tablets, gelatin film coated tablets, tablets coated with enteric coatings, tablets coated with films, double layered tablets and multi-layered tablets.</p>
    <p>For the purpose of shaping the pharmaceutical composition in the form of pills, any excipients which are known and widely used in this field can also be used, for example, carriers such as lactose, starch, coconut butter, hardened vegetable oils, kaolin, talc and the like; binders such as gum arabi powder, tragacanth gum powder, gelatin, ethanol and the like; disintegrating agents such as agar, laminalia and the like.</p>
    <p>For the purpose of shaping the pharmaceutical composition in the form of suppositories, any excipients which are known and widely used in this field can also be used, for example polyethylene glycols, coconut butter, higher alcohols, esters of higher alcohols, gelatin, semisynthesized glycerides and the like.</p>
    <p>For the purpose of shaping the pharmaceutical composition in the form of injection preparations, solutions and suspensions are sterilized and are preferably made isotonic to blood. In making injection preparations, any carriers which are usually used in this field can also be used, for example, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, fatty acid esters of polyoxyethylene sorbitan. In these instances, adequate amounts of sodium chloride, glucose or glycerin can be added to the desired injection preparations to make them isotonic. Furthermore, usual dissolving agents, buffer agents, analgesic agents may be added. Yet further, if necessary, coloring agents, preservatives, perfumes, seasoning agents, sweetening agents agents and other medicines may also be added to the desired preparations during the treatment of schizophrenia.</p>
    <p>The amount of carbostyril derivative of the general formula (1) or salt thereof to be contained in a pharmaceutical composition for treating schizophrenia according to the present invention is not specifically restricted and can suitably be selected from a wide range, usually it is contained 1 to 70%, preferably 1 to 30% by weight of the whole composition.</p>
    <p>Administration methods of a pharmaceutical composition for treating schizophrenia of the present invention are not specifically restricted, and can be administered in various forms of preparations depending on the age of the patient, distinction of sex, other conditions, as well as conditions of the symptoms. For example, tablets, pills, solutions, suspensions, emulsions, granules and capsules are orally administered; and injection preparations are administered singly or mixed with injection transfusions such as glucose solutions and amino acid solutions intravenously; and if necessary, the injection preparations are administered singly intramuscularly, intracutaneously, subcutaneously or intraperitoneally. Suppositories are administered into the rectum.</p>
    <p>The dosage of a pharmaceutical composition for treating schizophrenia according to the present invention are suitably selected according to the method of use, the age of the patient, distinction of sex, other conditions, as well as conditions of the symptoms, usually about 0.1 to 10 mg/kg of the body weight/day of carbostyril derivative of the general formula (1) as the active ingredient may be administered. Usually, 1 to 200 mg of the active ingredient may be contained in an administration unit form.</p>
    <p>In the above-mentioned formula (1), the C<sub>1</sub> -C<sub>3</sub> alkoxy group is a straight-chain or branched-chain alkoxy group having 1 to 3 carbon atoms, such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group and the like, and among these , methoxy group and ethoxy group are preferable, and ethoxy group is the most preferable. Furthermore, the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is preferably a single bond.</p>
    <p>The present invention will be explained in detail by showing Reference Examples, Examples, Pharmacological test results and Examples of Pharmaceutical Compositions, however, the present invention are not restricted only thereto.</p>
    <heading>Reference Example 1</heading> <p>To a mixture of 6.08 g of 2-chloro-3-methylaniline, 9 g of di(2-bromoethyl)amine hydrobromide and 4 ml of water was added a solution of 0.8 g of potassium hydorxide and 2.5 ml of water 3 times of 1 hour interval at 100° C., then the reaction mixture was stirred at the same temperature for 9 hours. To the resultant reaction mixture was added potassium hydroxide to make the mixture alkaline, and the mixture was extracted with diethyl ether, washed with water, dried with anhydrous magnesium sulfate. The solvent was removed by evaporation and the residue thus obtained was purified by means of a silica gel column chromatography (eluent: 5%-methanol/chloroform), and obtained 3.41 g of 4-(2-chloro-3-methylphenyl)piperazine.</p>
    <p>Light purple oily substance</p>
    <p> <sup>1</sup> H-NMR (CDCl<sub>3</sub>)δ: 2.38 (3H, s), 3.04 (8H, m), 6.93 (2H, m), 7.12 (1H, dd, J=7.7Hz, 7.7Hz)</p>
    <heading>Reference Examples 2-5</heading> <p>By procedures similar to those employed in the above mentioned Reference Example 1, by using suitable starting materials, there were prepared compounds of Reference Examples 2-5 as shown in the following Table 1.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________ ##STR15##ReferenceExample No.    R            <sup>1</sup> H-NMR (CDCl<sub>3</sub>) δ:______________________________________     ##STR16##   2.45 (3H, s), 2.90 (4H, m), 3.05 (4H, m), 7.23 (1H,                 dd, J=8.0Hz, 2.0Hz), 7.28 (1H, dd, J=7.4Hz, 8.0Hz),                 .52 (1H, dd, J=7.4Hz, 2.0Hz)3     ##STR17##   2.42 (3H, s), 3.03 (8H, m), 6.90 (1H, d, J=7.9Hz),                 6.95 (1H, d, J=7.5Hz), 7.17 (1H, dd, J=7.5Hz,                 7.9Hz)4     ##STR18##   3.05 (8H, m), 6.91 (1H, d, J=2.3Hz) 7.17 (1H, d,                 J=2.3Hz)5     ##STR19##   3.02 (8H, m), 6.98 (1H, dd, J=8.0Hz, 1.5Hz), 7.14                 (1H, t, J=8.0Hz) 7.35 (1H, dd, J=8.0Hz,______________________________________                 1.5Hz)</pre>
    
    <heading>Reference Example 6</heading> <p>To a solution of 4.06 g of potassium carbonate with 400 ml of water was added 40 g of 7-hydroxy-3,4-dihydrocarbostyril and 158 g of 1,4-dibromobutane, then the mixture was refluxed for 3 hours. The reaction mixture thus obtained was extracted with dichloromethane, dried with anhydrous magnesium sulfate, then the solvent was removed by evaporation. The residue thus obtained was purified by means of a silica gel column chromatography (eluent: dichloromethane), and recrystallized from n-hexane-ethanol to yield 50 g of 7-(4-bromobutoxy)-3,4-dihydrocarbostyril.</p>
    <p>Colorless needle crystals</p>
    <p>Melting point: 110.5°-111.0° C.</p>
    <heading>Example 1</heading> <p>A suspension of 47 g of 7-(4-bromobutoxy)-3,4-dihydrocarbostyril, 35 g of sodium iodide with 600 ml of acetonitrile was refluxed for 30 minutes. To this suspension was added 40 g of 1-(2,3-dichlorophenyl)piperazine and 33 ml of triethylamine and the whole mixture was further refluxed for 3 hours. After the solvent was removed by evaporation, the residue thus obtained was dissolved in chloroform, washed with water then dried with anhydrous magnesium sulfate. The solvent was removed by evaporation, and the residue thus obtained was recrystallized from ethanol twice, to yield 57.1 g of 7-{4-[-4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril</p>
    <p>Colorless flake crystals</p>
    <p>Melting point: 139.0°-139.5° C.</p>
    <p>One gram of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarboxtyril was dissolved in 20 ml of ethanol by heating, then under stirring condition, an ethanol solution saturated with hydrogen chloride was added thereto, the crystals precipitated were collected by filtration and recrystallized from thanol to yield 0.75 g of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril hydrochloride.</p>
    <p>White powdery substance</p>
    <p>Melting point: 214°-222° C. (decomposed).</p>
    <p>One gram of 7-[4-.4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril was dissolved in 10 ml of ethanol, then to this solution was added 4 ml of sulfuric acid-ethanol (1 ml of concentrated sulfuric acid/10 ml of ethanol), then the solvent was removed by evaporation. To the residue thus obtained was added 10 ml of ethanol and 30 ml of water, the mixture was heated to make it as a solution, recrystallized, and the crystals were collected by filtration, further recrystallized from ethanol-water to yield 1.02 g of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarboxtyril.multidot.sulfate.</p>
    <p>White powdery substance</p>
    <p>Melting point: 220°-225° C.</p>
    <p>By using 1.0 g of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril and 290 mg of fumaric acid, and treated by procedures similar to those employed in the case of preparation of the sulfate as mentioned above, and recrystallized from ethanol to yield 0.97 g of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril.multidot.fumarate.</p>
    <p>White powdery substance</p>
    <p>Melting point: 196°-198° C.</p>
    <p>By using 1.0 g of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarboxtyril and 290 mg of maleic acid, and treated by procedures similar to those employed in the case of preparation of the sulfate as mentioned above, and recrystallized from ethanol to yield 0.98 g of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl[butoxy}-3,4-dihydrocarbostyril.multidot.maleate.</p>
    <p>White powdery substance</p>
    <p>Melting point: 172°-180° C.</p>
    <heading>EXAMPLES 2-14</heading> <p>By using suitable starting materials, and by procedures similar to those employed in Example 1, there were prepared compounds of Examples 2-14 as shown in Table 2 as follows. In Table 2, compounds of Examples 11-14 are in the form of hydrochlorides.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 2__________________________________________________________________________ ##STR20##         Carbon-carbon         bond between         3- and 4-         positions in                 Crystal form                             MeltingExample       carbostyril                 (Recrystallization                             pointNo.  R        skeleton                 solvent)    (°C.)__________________________________________________________________________ ##STR21##         Single bond                 Yellow needle crystals (Methanol)                             165-1663 ##STR22##         Single bond                 Colorless flake crystals (Ethanol)                             133-1344 ##STR23##         Single bond                 Colorless needle crystals (Ethanol)                             125-1265 ##STR24##         Single bond                 White powdery substance (Ethanol)                             134-1356 ##STR25##         Single bond                 Colorless granular crystals (Ethanol)                             133-1347 ##STR26##         Single bond                 White powdery substance (Methanol)                             174-1768 ##STR27##         Single bond                 White powdery substance (Methanol)                             125-1269 ##STR28##         Single bond                 Pale brown flake crystals (Methanol)                             150-15110 ##STR29##         Double bond                 White powdery substance (Ethanol)                             144-14611 ##STR30##         Double bond                 White powdery substance  (Ethanol)                             151 (decomp.)12 ##STR31##         Single bond                 Colorless fine needle crystals (Ethanol)                             214-21813 ##STR32##         Single bond                 Pale brown powdery substance (Ethanol-diethyl                 ether)      207-207.514 ##STR33##         Single bond                 Pale brown powdery substance (Ethanol-diethyl                 ether)      203-203.5__________________________________________________________________________</pre>
    
    <heading>PHARMACOLOGICAL TESTS</heading> <heading>(a) Anti-apomorphine activity in mouse</heading> <p>Pharmacological test was conducted by using six mice in one test group. One hour after the oral administration of a test compound to a test mouse, apomorphine (1.25 mg/kg) was subcutaneously administered, and the stereotypy movements manifested were scored according to the method by Puech (Neuropharmacology, Vol. 20, pp. 1279, 1981). The anti-apomorphine activity performed by each of the test compounds were evaluated by the scored data as the indication thereof.</p>
    <p>50% Effective dose (ED<sub>50</sub>, mg/kg) of anti-apomorphine activity performed by a test compound is determined in that when the score obtained from the test group is lower than 50% of mean value of the score obtained from the control group, then it is defined as "positive" in anti-apomorphine activity.</p>
    <heading>(b) Anti-epinephrine lethal activity in mouse</heading> <p>By procedures similar to those described in Janssen, P., et al.: Arzneimittel Forschung, Vol. 13, pp. 205, (1963), the test was conducted by using six mice in one test group. One hour after the oral administration of a test compound to a test mouse, a lethal dose (1.5 mg/kg) of epinephrine was intravenously administered, and 4 hours after the intravenous administration, each of the mice in the test group was observed whether it is alive or not.</p>
    <p>50% Effective dose (ED<sub>50</sub>, mg/kg) of anti-epinephrine lethal activity performed by a test compound is determined from the amount thereof orally administered, and in the case that the mouse is alive is determined as "positive" in anti-epinephrine lethal activity.</p>
    <p>The test results are shown in Table 3 as follows.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________TestcompoundNo.______________________________________1            Compound of Example 1 (Free form)2            Compound of Example 23            Compound of Example 34            Compound of Example 45            Compound of Example 56            Compound of Example 127            Compound of Example 78            Compound of Example 89            Compound of Example 910           Compound of Example 1011           Compound of Example 1112           Compound of Example 1313           Compound of Example 14______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________Test    Anti-apomorphine                 Anti-epinephrinecompound   activity      activityNo.     (ED<sub>50</sub> mg/kg) (A)                 (ED<sub>50</sub> mg/kg) (B)                              (B)/(A)______________________________________1       0.18          &gt;128         &gt;7112       0.3           &gt;128         &gt;426.73       0.4           &gt;64          &gt;1604       0.4           &gt;64          &gt;1605       0.5           &gt;128         &gt;2566       0.1           3.7          377       0.4           &gt;128         &gt;3208       0.2           2.5          12.59       0.6           &gt;256         &gt;426.710      0.36          &gt;128         &gt;35511      0.12          3.8          31.612      0.5           1.58         3.1613      0.2           0.24         1.2______________________________________</pre>
    
    <heading>Example of Preparation of Pharmaceutical Composition -1</heading> <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________7-{4-[4-(2,3-dichlorophenyl)-1-                   5      mgpiperazinyl]butoxy}-3,4-dihydrocarbostyrilStarch                  132    mgMagnesium stearate      18     mgLactose                 45     mgTotal                   200    mg______________________________________</pre>
    
    <p>By using usual procedures, tablets containing the above formulation per one tablet were prepared.</p>
    <heading>Example of Preparation of Pharmaceutical Composition-2</heading> <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________7-{4-[4-(2-ethoxyphenyl)-1-                    500    mgpiperazinyl]-butoxy}-3,4-dihydrocarbostyrilPolyethylene glycol      0.3    g(Molecular weight: 4,000)Sodium chloride          0.9    gPolyoxyethylene sorbitan monooleate                    0.4    gSodium metabisulfite     0.1    gMethyl p-hydroxybenzoate 0.18   gPropyl p-hydroxybenzoate 0.02   gDistilled water for injection                    100    ml______________________________________</pre>
    
    <p>The above-mentioned methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sodium metabisulfite and sodium chloride were dissolved in distilled water for injection at 80° C. with stirring. The resulting solution was cooled to 40° C. then 7-{4-[4-(2-ethoxyphenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarboxtyril, polyethylene glycol and polyoxyethylene sorbitan monooelate were dissolved in the above-mentioned solution in this order, then the predetermined volume of the injection solution was adjusted by adding the distilled water for injection, and was sterilized by filtration by using a suitable filter paper, then 1 ml each of the desired injection solution was filled in an ampul.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4824840">US4824840</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 12, 1987</td><td class="patent-data-table-td patent-date-value">Apr 25, 1989</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Carbostyril derivatives and pharmaceutical preparations containing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=-rgvBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DJP%26NR%3DS58203968A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNEK5uG8dGtfq9Tjh7MsRWI07OIVrA">JPS58203968A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6977257">US6977257</a></td><td class="patent-data-table-td patent-date-value">Apr 24, 2002</td><td class="patent-data-table-td patent-date-value">Dec 20, 2005</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Aripiprazole oral solution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7053092">US7053092</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 2002</td><td class="patent-data-table-td patent-date-value">May 30, 2006</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Therapy for nervous system disorders; psychological disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7115587">US7115587</a></td><td class="patent-data-table-td patent-date-value">Aug 14, 2003</td><td class="patent-data-table-td patent-date-value">Oct 3, 2006</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Aripiprazole complex formulation and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7160888">US7160888</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2004</td><td class="patent-data-table-td patent-date-value">Jan 9, 2007</td><td class="patent-data-table-td ">Warner Lambert Company Llc</td><td class="patent-data-table-td ">7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one; use in the treatment of central nervous system disorders, bipolar disorder in a human</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7361756">US7361756</a></td><td class="patent-data-table-td patent-date-value">Feb 7, 2005</td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">by mixing 7-hydroxy-tetrahydroquinolinone, dibromobutane, and at least one base to form a reaction mixture; using phase transfer catalysts; or using a low boiling point solvent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7456181">US7456181</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2003</td><td class="patent-data-table-td patent-date-value">Nov 25, 2008</td><td class="patent-data-table-td ">Hetero Drugs Limited</td><td class="patent-data-table-td ">Aripiprazole crystalline forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7491726">US7491726</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 2003</td><td class="patent-data-table-td patent-date-value">Feb 17, 2009</td><td class="patent-data-table-td ">Hetero Drugs Limited</td><td class="patent-data-table-td ">Characterized by x-ray powder diffraction pattern having peaks expressed as 2 theta at 8.7, 11.6, 16.3, 17.7, 18.6, 20.3, 23.4, 24.9 degrees; stable and reproducible; preparation via crystalline forms of aripiprazole hydrochloride serves as a means of producing pure aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7504504">US7504504</a></td><td class="patent-data-table-td patent-date-value">Dec 16, 2004</td><td class="patent-data-table-td patent-date-value">Mar 17, 2009</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Methods of preparing aripiprazole crystalline forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7507823">US7507823</a></td><td class="patent-data-table-td patent-date-value">May 6, 2005</td><td class="patent-data-table-td patent-date-value">Mar 24, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Water is introduced to a stream of supercritical fluid which is then allowed to mix with a stream including a mixture including aripiprazole and a solvent; mixing results in the substantially simultaneous dispersion and extraction of the aripiprazole from the mixture by the supercritical fluid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7550445">US7550445</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2006</td><td class="patent-data-table-td patent-date-value">Jun 23, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Inclusion complex in a beta-cyclodextrin, preferably, sulfobutyl ether beta-cyclodextrin, in the form of an injectable material; reducing irritation normally caused by aripiprazole at an intramuscular injection site; for treating schizophrenia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7642353">US7642353</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td patent-date-value">Jan 5, 2010</td><td class="patent-data-table-td ">Synthon Bv</td><td class="patent-data-table-td ">crystallizing from a solvent selected from 1-propanol, 2-propanol, 1-butanol, ethyl acetate, acetonitrile</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7655798">US7655798</a></td><td class="patent-data-table-td patent-date-value">Mar 17, 2006</td><td class="patent-data-table-td patent-date-value">Feb 2, 2010</td><td class="patent-data-table-td ">Synthon Bv</td><td class="patent-data-table-td ">crystallizing aripiprazole Type II from a solution of aripiprazole dissolved in a solvent selected from 2-propanol, dimethylsulfoxide or mixture and optionally further comprising ethyl acetate; solid state Type II aripiprazole without the use of a solid state heat treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7658998">US7658998</a></td><td class="patent-data-table-td patent-date-value">Jan 21, 2004</td><td class="patent-data-table-td patent-date-value">Feb 9, 2010</td><td class="patent-data-table-td ">Alkermes Controlled Therapeutics, Inc.</td><td class="patent-data-table-td ">Mixture of biocompatibility polymer and active materials, drugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7714129">US7714129</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 2006</td><td class="patent-data-table-td patent-date-value">May 11, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Methods of preparing anhydrous aripiprazole form II</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7732597">US7732597</a></td><td class="patent-data-table-td patent-date-value">Sep 26, 2007</td><td class="patent-data-table-td patent-date-value">Jun 8, 2010</td><td class="patent-data-table-td ">Symed Labs Limited</td><td class="patent-data-table-td ">Prepared by acetylating (S)-N-[[3-[3-fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine in a solvent, optionally in presence of an organic base to form linezolid, seeding reaction mixture, and isolating linezolid form III; antibacterial agent; thermally stable</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7799790">US7799790</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2008</td><td class="patent-data-table-td patent-date-value">Sep 21, 2010</td><td class="patent-data-table-td ">Helm Ag</td><td class="patent-data-table-td ">Morphological stabilized; using mixture of stabilizers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7807680">US7807680</a></td><td class="patent-data-table-td patent-date-value">Oct 19, 2004</td><td class="patent-data-table-td patent-date-value">Oct 5, 2010</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Controlled release sterile injectable aripiprazole formulation and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7825125">US7825125</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2006</td><td class="patent-data-table-td patent-date-value">Nov 2, 2010</td><td class="patent-data-table-td ">Helm Ag</td><td class="patent-data-table-td ">Amorphous aripiprazole and process for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7872132">US7872132</a></td><td class="patent-data-table-td patent-date-value">Oct 8, 2004</td><td class="patent-data-table-td patent-date-value">Jan 18, 2011</td><td class="patent-data-table-td ">Suven Life Sciences Limited</td><td class="patent-data-table-td ">reacting 6-hydroxy-l-indanone with 1,4-dihalobutane in the presence of a base ( NaH), a solvent (methanol) to form a novel intermediate 6-(4-halo butoxy)-indan-1-one, reacting intermediate with 1-(2,3-clichlorophenyl)-piperazine to form another intermediate, reacting with sodim azide; aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7884205">US7884205</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2006</td><td class="patent-data-table-td patent-date-value">Feb 8, 2011</td><td class="patent-data-table-td ">Sandoz Ag</td><td class="patent-data-table-td ">Salts of aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7902198">US7902198</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td patent-date-value">Mar 8, 2011</td><td class="patent-data-table-td ">Synthon Bv</td><td class="patent-data-table-td ">Crystalline aripiprazole solvates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7910589">US7910589</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2007</td><td class="patent-data-table-td patent-date-value">Mar 22, 2011</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7964605">US7964605</a></td><td class="patent-data-table-td patent-date-value">May 29, 2008</td><td class="patent-data-table-td patent-date-value">Jun 21, 2011</td><td class="patent-data-table-td ">Sk Holdings Co., Ltd.</td><td class="patent-data-table-td ">Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7985752">US7985752</a></td><td class="patent-data-table-td patent-date-value">May 29, 2009</td><td class="patent-data-table-td patent-date-value">Jul 26, 2011</td><td class="patent-data-table-td ">Sk Holdings Co., Ltd.</td><td class="patent-data-table-td ">Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8008490">US8008490</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2006</td><td class="patent-data-table-td patent-date-value">Aug 30, 2011</td><td class="patent-data-table-td ">Sandoz Ag</td><td class="patent-data-table-td ">Polymorphic forms of aripiprazole and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8017615">US8017615</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2007</td><td class="patent-data-table-td patent-date-value">Sep 13, 2011</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8030312">US8030312</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2004</td><td class="patent-data-table-td patent-date-value">Oct 4, 2011</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Administering therapeutically effective amount of a carbostyril derivative compound for therapy of nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8030313">US8030313</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 31, 2007</td><td class="patent-data-table-td patent-date-value">Oct 4, 2011</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Controlled release sterile injectable aripiprazole formulation and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8039621">US8039621</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2007</td><td class="patent-data-table-td patent-date-value">Oct 18, 2011</td><td class="patent-data-table-td ">Cambrex Charles City, Inc.</td><td class="patent-data-table-td ">Process for preparing anhydrous Aripirazole type I</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093387">US8093387</a></td><td class="patent-data-table-td patent-date-value">Dec 24, 2009</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Synthon Bv</td><td class="patent-data-table-td ">Process of making crystalline type II aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8338427">US8338427</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 15, 2008</td><td class="patent-data-table-td patent-date-value">Dec 25, 2012</td><td class="patent-data-table-td ">Alkermes, Inc.</td><td class="patent-data-table-td ">Methods for administering aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8338428">US8338428</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 15, 2012</td><td class="patent-data-table-td patent-date-value">Dec 25, 2012</td><td class="patent-data-table-td ">Alkermes, Inc.</td><td class="patent-data-table-td ">Methods for administering aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8399469">US8399469</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2007</td><td class="patent-data-table-td patent-date-value">Mar 19, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8426423">US8426423</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2007</td><td class="patent-data-table-td patent-date-value">Apr 23, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">e.g. 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyril; serotonin receptor agonist; antidepressant, anxilytic agent; psychological disorders; autism, Down&#39;s syndrome, attention deficit hyper-activity disorder (ADHD), Alzheimer&#39;s disease, Parkinson&#39;s disease ,</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8431576">US8431576</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 2010</td><td class="patent-data-table-td patent-date-value">Apr 30, 2013</td><td class="patent-data-table-td ">Alkermes Pharma Ireland Limited</td><td class="patent-data-table-td ">Heterocyclic compounds for the treatment of neurological and psychological disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8518421">US8518421</a></td><td class="patent-data-table-td patent-date-value">May 16, 2011</td><td class="patent-data-table-td patent-date-value">Aug 27, 2013</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Flashmelt oral dosage formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8529949">US8529949</a></td><td class="patent-data-table-td patent-date-value">Mar 17, 2006</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">Synthon Bv</td><td class="patent-data-table-td ">Pharmaceutical tablets of crystalline type II aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8580796">US8580796</a></td><td class="patent-data-table-td patent-date-value">Jan 13, 2012</td><td class="patent-data-table-td patent-date-value">Nov 12, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8592427">US8592427</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 2011</td><td class="patent-data-table-td patent-date-value">Nov 26, 2013</td><td class="patent-data-table-td ">Alkermes Pharma Ireland Limited</td><td class="patent-data-table-td ">Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8604041">US8604041</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 2011</td><td class="patent-data-table-td patent-date-value">Dec 10, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Method of treating panic disorder</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8623874">US8623874</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 2008</td><td class="patent-data-table-td patent-date-value">Jan 7, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Method of treating neurodegenerative diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8642600">US8642600</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 19, 2011</td><td class="patent-data-table-td patent-date-value">Feb 4, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Method of treating autism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8642760">US8642760</a></td><td class="patent-data-table-td patent-date-value">Jun 23, 2011</td><td class="patent-data-table-td patent-date-value">Feb 4, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8680105">US8680105</a></td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td patent-date-value">Mar 25, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Method of treating down&#39;s syndrome</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8686009">US8686009</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 2010</td><td class="patent-data-table-td patent-date-value">Apr 1, 2014</td><td class="patent-data-table-td ">Alkermes Pharma Ireland Limited</td><td class="patent-data-table-td ">Prodrugs of NH-acidic compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8703772">US8703772</a></td><td class="patent-data-table-td patent-date-value">Aug 25, 2011</td><td class="patent-data-table-td patent-date-value">Apr 22, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8703773">US8703773</a></td><td class="patent-data-table-td patent-date-value">May 21, 2012</td><td class="patent-data-table-td patent-date-value">Apr 22, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8722679">US8722679</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2007</td><td class="patent-data-table-td patent-date-value">May 13, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Controlled release sterile injectable aripiprazole formulation and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8722680">US8722680</a></td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td patent-date-value">May 13, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Method of treating neurodegenerative diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759346">US8759346</a></td><td class="patent-data-table-td patent-date-value">Mar 26, 2010</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Organic compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759350">US8759350</a></td><td class="patent-data-table-td patent-date-value">Dec 25, 2003</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759351">US8759351</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 10, 2012</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Methods for administering aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8772299">US8772299</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 2011</td><td class="patent-data-table-td patent-date-value">Jul 8, 2014</td><td class="patent-data-table-td ">Sk Biopharmaceuticals Co., Ltd.</td><td class="patent-data-table-td ">Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20100113784">US20100113784</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 24, 2007</td><td class="patent-data-table-td patent-date-value">May 6, 2010</td><td class="patent-data-table-td ">Niraj Shyamlal Shah</td><td class="patent-data-table-td ">Process for preparing crystalline aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110281889">US20110281889</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 19, 2011</td><td class="patent-data-table-td patent-date-value">Nov 17, 2011</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">5-HT1A Receptor Subtype Agonist</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN1512884B?cl=en">CN1512884B</a></td><td class="patent-data-table-td patent-date-value">Apr 24, 2002</td><td class="patent-data-table-td patent-date-value">May 26, 2010</td><td class="patent-data-table-td ">布里斯托尔-迈尔斯斯奎布公司</td><td class="patent-data-table-td ">阿立哌唑口服溶液</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN1870980B?cl=en">CN1870980B</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2004</td><td class="patent-data-table-td patent-date-value">Jun 23, 2010</td><td class="patent-data-table-td ">大冢制药株式会社</td><td class="patent-data-table-td ">Controlled release sterile injectable aripiprazole formulation and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN100432053C?cl=en">CN100432053C</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 2005</td><td class="patent-data-table-td patent-date-value">Nov 12, 2008</td><td class="patent-data-table-td ">上海医药工业研究院</td><td class="patent-data-table-td ">Crystalline Alipiprazole and its prepn</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN101068789B?cl=en">CN101068789B</a></td><td class="patent-data-table-td patent-date-value">Oct 8, 2004</td><td class="patent-data-table-td patent-date-value">Dec 15, 2010</td><td class="patent-data-table-td ">苏文生命科学有限公司</td><td class="patent-data-table-td ">Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1660037A2?cl=en">EP1660037A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 29, 2004</td><td class="patent-data-table-td patent-date-value">May 31, 2006</td><td class="patent-data-table-td ">Alkermes Controlled Therapeutics II, Inc.</td><td class="patent-data-table-td ">Methods for administering aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1723957A2?cl=en">EP1723957A2</a></td><td class="patent-data-table-td patent-date-value">Dec 25, 2003</td><td class="patent-data-table-td patent-date-value">Nov 22, 2006</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1845088A1?cl=en">EP1845088A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 10, 2007</td><td class="patent-data-table-td patent-date-value">Oct 17, 2007</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">An improved process for the preparation of aripipirazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1925308A1?cl=en">EP1925308A1</a></td><td class="patent-data-table-td patent-date-value">Sep 25, 2002</td><td class="patent-data-table-td patent-date-value">May 28, 2008</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole (crystal G) drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1927355A1?cl=en">EP1927355A1</a></td><td class="patent-data-table-td patent-date-value">Sep 25, 2002</td><td class="patent-data-table-td patent-date-value">Jun 4, 2008</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole (crystal F) drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1927356A1?cl=en">EP1927356A1</a></td><td class="patent-data-table-td patent-date-value">Sep 25, 2002</td><td class="patent-data-table-td patent-date-value">Jun 4, 2008</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole (crystal D) drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1927357A2?cl=en">EP1927357A2</a></td><td class="patent-data-table-td patent-date-value">Sep 25, 2002</td><td class="patent-data-table-td patent-date-value">Jun 4, 2008</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Low hygroscopic aripiprazole (crystal E) drug substance and processes for the preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1972628A1?cl=en">EP1972628A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 21, 2007</td><td class="patent-data-table-td patent-date-value">Sep 24, 2008</td><td class="patent-data-table-td ">Schwarz Pharma Ag</td><td class="patent-data-table-td ">Indolizines and aza-analog derivatives thereof as CNS active compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2082735A1?cl=en">EP2082735A1</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 2008</td><td class="patent-data-table-td patent-date-value">Jul 29, 2009</td><td class="patent-data-table-td ">Helm AG</td><td class="patent-data-table-td ">Amorphous Aripiprazole and Process for the Preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2093217A1?cl=en">EP2093217A1</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2006</td><td class="patent-data-table-td patent-date-value">Aug 26, 2009</td><td class="patent-data-table-td ">Sandoz AG</td><td class="patent-data-table-td ">Polymorph and solvates of aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2135609A1?cl=en">EP2135609A1</a></td><td class="patent-data-table-td patent-date-value">Nov 3, 2005</td><td class="patent-data-table-td patent-date-value">Dec 23, 2009</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">Combinations of nicotinic acetylcholine alpha 7 receptor agonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2223916A1?cl=en">EP2223916A1</a></td><td class="patent-data-table-td patent-date-value">Oct 28, 2004</td><td class="patent-data-table-td patent-date-value">Sep 1, 2010</td><td class="patent-data-table-td ">Eli Lilly and Company</td><td class="patent-data-table-td ">Morpholine derivatives as norepinephrine reuptake inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2279727A2?cl=en">EP2279727A2</a></td><td class="patent-data-table-td patent-date-value">Sep 13, 2006</td><td class="patent-data-table-td patent-date-value">Feb 2, 2011</td><td class="patent-data-table-td ">Elan Pharma International Limited</td><td class="patent-data-table-td ">Nanoparticulate aripiprazole formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2332537A1?cl=en">EP2332537A1</a></td><td class="patent-data-table-td patent-date-value">Nov 3, 2005</td><td class="patent-data-table-td patent-date-value">Jun 15, 2011</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">Combinations of nicotinic acetylcholine alpha 7 receptor agonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2336129A1?cl=en">EP2336129A1</a></td><td class="patent-data-table-td patent-date-value">Jun 17, 2005</td><td class="patent-data-table-td patent-date-value">Jun 22, 2011</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">1-aza-bicyclo[3.3.1]nonanes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2340810A1?cl=en">EP2340810A1</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2004</td><td class="patent-data-table-td patent-date-value">Jul 6, 2011</td><td class="patent-data-table-td ">Alkermes, Inc.</td><td class="patent-data-table-td ">Aripiprazole injectable suspension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2354141A1?cl=en">EP2354141A1</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2006</td><td class="patent-data-table-td patent-date-value">Aug 10, 2011</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">(1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2361914A1?cl=en">EP2361914A1</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2006</td><td class="patent-data-table-td patent-date-value">Aug 31, 2011</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">[(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2436384A2?cl=en">EP2436384A2</a></td><td class="patent-data-table-td patent-date-value">Apr 24, 2002</td><td class="patent-data-table-td patent-date-value">Apr 4, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Aripiprazole oral solution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2457911A1?cl=en">EP2457911A1</a></td><td class="patent-data-table-td patent-date-value">Jul 13, 2005</td><td class="patent-data-table-td patent-date-value">May 30, 2012</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2463278A1?cl=en">EP2463278A1</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2006</td><td class="patent-data-table-td patent-date-value">Jun 13, 2012</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2468732A1?cl=en">EP2468732A1</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2006</td><td class="patent-data-table-td patent-date-value">Jun 27, 2012</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">1H-Quinazoline-2,4-diones</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2476671A1?cl=en">EP2476671A1</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2006</td><td class="patent-data-table-td patent-date-value">Jul 18, 2012</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">1H-Quinazoline-2,4-diones</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2497476A1?cl=en">EP2497476A1</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2004</td><td class="patent-data-table-td patent-date-value">Sep 12, 2012</td><td class="patent-data-table-td ">Alkermes, Inc.</td><td class="patent-data-table-td ">Aripiprazole pamoate salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2601953A1?cl=en">EP2601953A1</a></td><td class="patent-data-table-td patent-date-value">May 19, 2004</td><td class="patent-data-table-td patent-date-value">Jun 12, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Carbostyril derivatives and mood stabilizers for treating mood disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2002085366A1?cl=en">WO2002085366A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 24, 2002</td><td class="patent-data-table-td patent-date-value">Oct 31, 2002</td><td class="patent-data-table-td ">Joyce Chou</td><td class="patent-data-table-td ">Aripiprazole oral solution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004017897A2?cl=en">WO2004017897A2</a></td><td class="patent-data-table-td patent-date-value">Aug 14, 2003</td><td class="patent-data-table-td patent-date-value">Mar 4, 2004</td><td class="patent-data-table-td ">Mark Dominick</td><td class="patent-data-table-td ">Aripiprazole complex formulation and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004105682A2?cl=en">WO2004105682A2</a></td><td class="patent-data-table-td patent-date-value">May 19, 2004</td><td class="patent-data-table-td patent-date-value">Dec 9, 2004</td><td class="patent-data-table-td ">Otsuka Pharma Co Ltd</td><td class="patent-data-table-td ">Carbostyril derivatives and mood stabilizers for treating mood disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005009990A1?cl=en">WO2005009990A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 25, 2003</td><td class="patent-data-table-td patent-date-value">Feb 3, 2005</td><td class="patent-data-table-td ">Hetero Drugs Ltd</td><td class="patent-data-table-td ">Aripiprazole crystalline forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005016262A2?cl=en">WO2005016262A2</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2004</td><td class="patent-data-table-td patent-date-value">Feb 24, 2005</td><td class="patent-data-table-td ">Alkermes Inc</td><td class="patent-data-table-td ">Methods for administering aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005041937A2?cl=en">WO2005041937A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 18, 2004</td><td class="patent-data-table-td patent-date-value">May 12, 2005</td><td class="patent-data-table-td ">Otsuka Pharma Co Ltd</td><td class="patent-data-table-td ">Controlled release sterile injectable aripiprazole formulation and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005047272A1?cl=en">WO2005047272A1</a></td><td class="patent-data-table-td patent-date-value">Oct 28, 2004</td><td class="patent-data-table-td patent-date-value">May 26, 2005</td><td class="patent-data-table-td ">Lilly Co Eli</td><td class="patent-data-table-td ">Morpholine derivatives as norepinephrine reuptake inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005077904A1?cl=en">WO2005077904A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 7, 2005</td><td class="patent-data-table-td patent-date-value">Aug 25, 2005</td><td class="patent-data-table-td ">Alisa Berlin</td><td class="patent-data-table-td ">Process for preparing aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005107808A2?cl=en">WO2005107808A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 29, 2005</td><td class="patent-data-table-td patent-date-value">Nov 17, 2005</td><td class="patent-data-table-td ">Michael Aaron Brodney</td><td class="patent-data-table-td ">Combination of atypical antipsychotics and 5-ht1b receptor antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006012237A2?cl=en">WO2006012237A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 24, 2005</td><td class="patent-data-table-td patent-date-value">Feb 2, 2006</td><td class="patent-data-table-td ">Shanghai Inst Pharm Industry</td><td class="patent-data-table-td ">Aripiprazole crystaline forms and associated methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006038220A1?cl=en">WO2006038220A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 8, 2004</td><td class="patent-data-table-td patent-date-value">Apr 13, 2006</td><td class="patent-data-table-td ">Suven Lifesciences Ltd</td><td class="patent-data-table-td ">Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006053780A1?cl=en">WO2006053780A1</a></td><td class="patent-data-table-td patent-date-value">Nov 17, 2005</td><td class="patent-data-table-td patent-date-value">May 26, 2006</td><td class="patent-data-table-td ">Synthon Bv</td><td class="patent-data-table-td ">Crystalline aripiprazole solvates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006108591A1?cl=en">WO2006108591A1</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2006</td><td class="patent-data-table-td patent-date-value">Oct 19, 2006</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007041414A1?cl=en">WO2007041414A1</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 2006</td><td class="patent-data-table-td patent-date-value">Apr 12, 2007</td><td class="patent-data-table-td ">Teva Pharma</td><td class="patent-data-table-td ">Methods of preparing anhydrous aripiprazole form ii</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007113846A1?cl=en">WO2007113846A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 22, 2006</td><td class="patent-data-table-td patent-date-value">Oct 11, 2007</td><td class="patent-data-table-td ">Alembic Ltd</td><td class="patent-data-table-td ">A process for the preparation of aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007148191A2?cl=en">WO2007148191A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 18, 2007</td><td class="patent-data-table-td patent-date-value">Dec 27, 2007</td><td class="patent-data-table-td ">Manoharan Muthutamizh</td><td class="patent-data-table-td ">An improved process for the preparation of aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008001188A2?cl=en">WO2008001188A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 26, 2007</td><td class="patent-data-table-td patent-date-value">Jan 3, 2008</td><td class="patent-data-table-td ">Cadila Pharmaceuticals Ltd</td><td class="patent-data-table-td ">An improved process for the preparation of substantially pure aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008024481A2?cl=en">WO2008024481A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 24, 2007</td><td class="patent-data-table-td patent-date-value">Feb 28, 2008</td><td class="patent-data-table-td ">Concert Pharmaceuticals Inc</td><td class="patent-data-table-td ">3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008113559A2?cl=en">WO2008113559A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 18, 2008</td><td class="patent-data-table-td patent-date-value">Sep 25, 2008</td><td class="patent-data-table-td ">Sanol Arznei Schwarz Gmbh</td><td class="patent-data-table-td ">Indolizines and aza-analog derivatives thereof as cns active compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010106551A2?cl=en">WO2010106551A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 9, 2010</td><td class="patent-data-table-td patent-date-value">Sep 23, 2010</td><td class="patent-data-table-td ">Neuland Laboratories Ltd.</td><td class="patent-data-table-td ">A process for the manufacture of pure anhydrous aripiprazole form b</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011023796A1?cl=en">WO2011023796A1</a></td><td class="patent-data-table-td patent-date-value">Aug 27, 2010</td><td class="patent-data-table-td patent-date-value">Mar 3, 2011</td><td class="patent-data-table-td ">Abbott Healthcare Products B.V.</td><td class="patent-data-table-td ">Bifeprunox for treating addiction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011030213A1?cl=en">WO2011030213A1</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td patent-date-value">Mar 17, 2011</td><td class="patent-data-table-td ">Jubilant Organosys Limited</td><td class="patent-data-table-td ">Improved process for the preparation of 7.(4-bromobutoxy) 3,4-dihydrocarbostyril, a precursor of aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012026562A1?cl=en">WO2012026562A1</a></td><td class="patent-data-table-td patent-date-value">Aug 19, 2011</td><td class="patent-data-table-td patent-date-value">Mar 1, 2012</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012067141A1?cl=en">WO2012067141A1</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2011</td><td class="patent-data-table-td patent-date-value">May 24, 2012</td><td class="patent-data-table-td ">Arte Corporation</td><td class="patent-data-table-td ">Two-chambered container-cum-syringe and syringe-filled aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012102216A1?cl=en">WO2012102216A1</a></td><td class="patent-data-table-td patent-date-value">Jan 17, 2012</td><td class="patent-data-table-td patent-date-value">Aug 2, 2012</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012129156A1?cl=en">WO2012129156A1</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2012</td><td class="patent-data-table-td patent-date-value">Sep 27, 2012</td><td class="patent-data-table-td ">Alkermes, Inc.</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising sorbitan esters</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012131451A1?cl=en">WO2012131451A1</a></td><td class="patent-data-table-td patent-date-value">Mar 5, 2012</td><td class="patent-data-table-td patent-date-value">Oct 4, 2012</td><td class="patent-data-table-td ">Jubilant Life Sciences Limited</td><td class="patent-data-table-td ">Process for producing aripiprazole in anhydrous type i crystals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012169662A1?cl=en">WO2012169662A1</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 2012</td><td class="patent-data-table-td patent-date-value">Dec 13, 2012</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Freeze-dried aripiprazole formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013002420A1?cl=en">WO2013002420A1</a></td><td class="patent-data-table-td patent-date-value">Jun 29, 2012</td><td class="patent-data-table-td patent-date-value">Jan 3, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Method for producing fine particles of aripiprazole anhydride crystals b</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013133448A1?cl=en">WO2013133448A1</a></td><td class="patent-data-table-td patent-date-value">Mar 6, 2013</td><td class="patent-data-table-td patent-date-value">Sep 12, 2013</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Sustained release oral solid preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014059363A1?cl=en">WO2014059363A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 11, 2013</td><td class="patent-data-table-td patent-date-value">Apr 17, 2014</td><td class="patent-data-table-td ">Antrim Pharmaceuticals Llc</td><td class="patent-data-table-td ">Oral solution formulations of aripiprazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014080285A2?cl=en">WO2014080285A2</a></td><td class="patent-data-table-td patent-date-value">Sep 19, 2013</td><td class="patent-data-table-td patent-date-value">May 30, 2014</td><td class="patent-data-table-td ">Alkermes Pharma Ireland Limited</td><td class="patent-data-table-td ">Pharmaceutical compositions having improved storage stability</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S253070">514/253.07</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc544/defs544.htm&usg=AFQjCNEPhTGhs9jAQ8SMbpXNH1ahRlM5vQ#C544S363000">544/363</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0215227000">C07D215/227</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0215220000">C07D215/22</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=-rgvBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D215/227">C07D215/227</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07D215/227</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Aug 21, 2007</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 31, 2007</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 13, 2006</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-21 IS CONFIRMED. NEW CLAIMS 22-24 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 14, 2005</td><td class="patent-data-table-td ">356</td><td class="patent-data-table-td ">Patent term extension under 35 u.s.c. 156</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">PRODUCT NAME: ABILIFY</span></div><div class="nested-key-value"><span class="nested-key">Expiry date: </span><span class="nested-value">20091020</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 28, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040811</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 10, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">OTSUKA PHARMACEUTICAL CO., LTD., MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF ASSIGNEE INFORMATION NOTICE;ASSIGNOR:OTSUKA PHARMACEUTICAL CO., LTD.;REEL/FRAME:014402/0284</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040308</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">OTSUKA PHARMACEUTICAL CO., LTD. 2440 RESEARCH BOUL</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF ASSIGNEE INFORMATION NOTICE;ASSIGNOR:OTSUKA PHARMACEUTICAL CO., LTD. /AR;REEL/FRAME:014402/0284</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 18, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">OTSUKA PHARMACEUTICAL CO., LTD., MARYLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF MAILING ADDRESS;ASSIGNOR:OTSUKA PHARMACEUTICAL CO., LTD.;REEL/FRAME:014344/0813</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040210</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">OTSUKA PHARMACEUTICAL CO., LTD. 2440 RESEARCH BOUL</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF MAILING ADDRESS;ASSIGNOR:OTSUKA PHARMACEUTICAL CO., LTD. /AR;REEL/FRAME:014344/0813</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 19, 2002</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 1, 1998</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 26, 1994</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 27, 1993</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 20, 1989</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">OTSUKA PHARMACEUTICAL CO., LTD., A CORP. OF JAPAN,</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:OSHIRO, YASUO;SATO, SEIJI;KURAHASHI, NOBUYUKI;REEL/FRAME:005162/0548</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19891013</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U0XkIqG-r-Fh3TUrkJtF1OG8vOBiw\u0026id=-rgvBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0K7a6f9TvD2UgsHcN7zb4_t8WAqQ\u0026id=-rgvBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U0MTwuBMX_r_rozlhHYPsiATf6Nuw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Treating_schizophrenia.pdf?id=-rgvBAABERAJ\u0026output=pdf\u0026sig=ACfU3U3z-9-DznZKbr23PT3WCo7S7zklpw"},"sample_url":"http://www.google.com/patents/reader?id=-rgvBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>